Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial.

ABSTRACT:

Background

Anamorelin, a ghrelin receptor agonist, has shown efficacy in lung cancer cachexia. We conducted the first randomized controlled trial to evaluate its effects in gastric cancer cachexia.

Methods

In this multicenter, open-label randomized controlled trial conducted across 10 hospitals in Japan, patients with unresectable or recurrent gastric cancer and cachexia receiving chemotherapy (1st-3rd line) were randomized (1:1) to receive oral anamorelin 100 mg daily for 12 weeks (Group A) or no anamorelin (Group N). Randomization was conducted using a computer-generated sequence, stratified be participating institution and the type of surgical procedure. The primary endpoint was the change in lean body mass (LBM) at 8 weeks. The primary, secondary, and safety analyses wer

SUBMITTER: Yamamoto K 

PROVIDER: S-EPMC12572812 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature